| Literature DB >> 36030250 |
Li-Ming Wang1, Bor-Kang Jong1, Chun-Kai Liao1, Ya-Ting Kou1, Yih-Jong Chern1, Yu-Jen Hsu1, Pao-Shiu Hsieh1, Wen-Sy Tsai1, Jeng-Fu You2.
Abstract
BACKGROUND: Few studies have evaluated the feasibility and safety of intracorporeal anastomosis (IA) for left hemicolectomy. Here, we aimed to investigate the potential advantages and disadvantages of laparoscopic left hemicolectomy with IA and compare the short- and medium-term outcomes between IA and extracorporeal anastomosis (EA).Entities:
Keywords: Disease-free survival; Extracorporeal anastomosis; Intracorporeal anastomosis; Laparoscopy surgery; Left hemicolectomy
Mesh:
Substances:
Year: 2022 PMID: 36030250 PMCID: PMC9419322 DOI: 10.1186/s12957-022-02735-7
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 3.253
Fig. 1Flow chart of the patient selection process
Patient characteristics and operative parameters of the intracorporeal and extracorporeal anastomosis groups
| IAa ( | EAb ( | ||
|---|---|---|---|
| Age (years) | 61.45 ± 11.9 | 62.65 ± 13.5 | 0.637 |
| Sex, | |||
| Male | 23 (57.5) | 45 (58.4) | 0.923 |
| Female | 17 (42.5) | 32 (41.6) | |
| BMIc (kg/m2) | 23.92 ± 3.1 | 23.94 ± 4.6 | 0.977 |
| Comorbidity, | |||
| Hypertension | 16 (40.0) | 23 (29.9) | 0.27 |
| Cardiac disease | 5 (12.5) | 2 (2.6) | 0.032 |
| CVAd | 0 (0) | 4 (5.2) | 0.142 |
| Diabetes mellitus | 10 (25) | 9 (11.7) | 0.064 |
| Cirrhosis | 1 (2.5) | 1 (1.3) | 0.634 |
| ASAe classification, | 0.424 | ||
| 2 | 15 (37.5) | 34 (44.2) | |
| 3 | 25 (62.5) | 41 (53.2) | |
| 4 | 0 (0) | 2 (2.6) | |
| Previous abdominal surgery, | 6 (15.0) | 18 (23.4) | 0.287 |
| Location, | |||
| Transverse colon | 10 (25) | 29 (37.7) | 0.387 |
| Splenic flexure | 5 (12.5) | 8 (10.4) | |
| Descending colon | 25 (62.5) | 40 (51.9) | |
| Preoperative albumin | 4.29 ± 0.3 | 4.19 ± 0.4 | 0.231 |
| Operative time (mins) | 240 ± 61.0 | 241 ± 68.9 | 0.906 |
| Blood loss (mL) | 33.7 ± 31.2 | 66.1 ± 201.9 | 0.397 |
Abbreviations: aIntracorporeal anastomosis, bExtracorporeal anastomosis, cBody mass index, dCerebrovascular accident, eAmerican Society of Anesthesiologists
Pathologic parameters of the intracorporeal and extracorporeal anastomosis groups
| IAa ( | EAb ( | ||
|---|---|---|---|
| p T stage | |||
| T0 | 2 (5) | 0 (0) | 0.067 |
| T1 | 9 (22.5) | 12 (15.6) | |
| T2 | 6 (15) | 10 (13) | |
| T3 | 22 (55) | 40 (51.9) | |
| T4a | 1 (2.5) | 12 (15.6) | |
| T4b | 0 (0) | 3 (3.9) | |
| p N stage | |||
| N0 | 30 (75) | 50 (64.9) | 0.25 |
| N1 | 10 (25) | 19 (24.7) | |
| N2 | 0 (0) | 8 (10.4) | |
| TNM stage | 0.179 | ||
| Stage 0 | 2 (5) | 0 (0) | |
| Stage 1 | 9 (22.5) | 21 (27.3) | |
| Stage 2 | 18 (45) | 29 (37.7) | |
| Stage 3 | 11 (27.5) | 27 (35.1) | |
| Differentiation, | 0.456 | ||
| Well | 6 (15) | 6 (7.8) | |
| Medium | 30 (75) | 64 (83.1) | |
| Poor | 4 (10) | 7 (9.1) | |
| Angiolymphatic invasion, | 9 (22.5) | 18 (23.4) | 0.915 |
| Perineural invasion, | 6 (15) | 19 (24.7) | 0.226 |
| Tumor size (cm) | |||
| Width | 3.0 ± 1.8 | 3.5 ± 2.3 | 0.223 |
| Length | 2.7 ± 1.7 | 3.0 ± 1.6 | 0.409 |
| Specimen length (cm) | 17.7 ± 5.8 | 17.6 ± 5.9 | 0.951 |
| Nearest margin (cm) | 5.0 ± 2.3 | 4.8 ±1.9 | 0.593 |
| Harvested lymph nodes (n) | 25.0 ± 10.2 | 32.2 ± 22.3 | 0.058 |
Abbreviations: aIntracorporeal anastomosis, bExtracorporeal anastomosis
Short-term outcomes of the intracorporeal and extracorporeal anastomosis groups
| IAa ( | EAb ( | ||
|---|---|---|---|
| Pain scale, NRSc | |||
| PODd 0 | 4.5 ± 2.0 | 4.0 ± 1.8 | 0.158 |
| PODd 1 | 3.6 ± 1.8 | 4.0 ± 1.8 | 0.301 |
| PODd 2 | 2.8 ± 1.3 | 2.9 ± 1.5 | 0.665 |
| PODd 3 | 2.2 ± 1.0 | 2.3 ± 1.0 | 0.659 |
| Morphine (mg) | 10.6 ± 1.4 | 10.9 ± 1.6 | 0.906 |
| Bowel movement (days) | |||
| Time to first flatus passage | 2.1 ± 1.1 | 2.5 ± 1.6 | 0.234 |
| Time to first stool passage | 3.7 ±2.3 | 4.6 ± 2.5 | 0.067 |
| Tolerate liquid diet | 2.9 ± 1.6 | 4.4 ± 3.0 | 0.006 |
| Tolerate soft diet | 4.6 ± 1.9 | 6.1 ± 3.1 | 0.007 |
Abbreviations: aIntracorporeal anastomosis, bExtracorporeal anastomosis, cNumeric rating scale, dPostoperative day, eWhite blood cell, fC-reactive protein
Fig. 2Two-year overall survival rates of the IA and EA groups. Blue bars, intracorporeal anastomosis (IA); red bars, extracorporeal anastomosis (EA)
Fig. 3Two-year disease-free survival rates of the IA and EA groups. Blue bars, intracorporeal anastomosis (IA); red bars, extracorporeal anastomosis (EA)
Medium-term outcomes of the intracorporeal and extracorporeal anastomosis groups
| IAa ( | EAb ( | ||
|---|---|---|---|
| Medium follow-up (months) | 35.4 ± 8.9 | 40.2 ± 16.1 | 0.068 |
| Recurrence, | 1 (2.5) | 7 (9.1) | 0.18 |
| Liver | 0 (0) | 5 (6.5) | 0.1 |
| Lung | 0 (2) | 2 (2.6) | 0.304 |
| Carcinomatosis | 1 (2.5) | 3 (3.9) | 0.693 |
| Death, | 2 (5) | 5 (6.5) | 0.747 |
| 2-year disease-free survival (%) | 97.5 | 90.9 | 0.182 |
| Survival (%) | 38 (95) | 72 (93.5) | 0.747 |
Abbreviations: aIntracorporeal anastomosis, bExtracorporeal anastomosis